News

U.S. Department of Justice Close Investigation PLATO Clinical Trial Ticagrelor

AstraZeneca announced it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial that tested the safety and...

July 30, 2014 — Regado Biosciences announced earlier this month it has voluntarily paused enrollment in its REGULATE-PCI trial, which was testing the safety and effectiveness of its Revolixys...

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve. These findings from the first phase of a...

June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death and need for...

Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere lNRatio2 PT/INR monitoring system (professional use) which also consists of the INRatio2 monitor...

April 29, 2014 — Armetheon Inc. announced it has reached agreement with the U.S. Food and Drug Administration (FDA) on a special protocol assessment (SPA) for the final pivotal trial of tecarfarin...

April 10, 2014 — The 2014 Guideline for the Management of Patients With Atrial Fibrillation includes recommendations for an increased use of radio frequency (RF) ablation in the treatment of non-...

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary...

Patient enrollment has been completed four months ahead of plan in the Phase III clinical trial EUCLID study for AstraZeneca's ticagrelor (Brilinta) tablets. Part of PARTHENON,...

Medtronic Endeavor Stents Drug-eluting Antiplatelet Therapy Clinical Study

Patients with coronary artery disease who received an Endeavor or Resolute drug-eluting stent from Medtronic Inc. and subsequently interrupted their dual ...

Janssen Research & Development LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) issued complete response letters (CRLs) regarding supplemental New Drug Applications (sNDAs)...

Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke...

A large-scale analysis assessing the real-world risk of venous thromboembolism (VTE) in chemotherapy patients...

The U.S. Food and Drug Administration (FDA)’s Cardiovascular and Renal Drugs Advisory Committee recommended approval of vorapaxar, Merck’s investigational ...

The U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee voted against the approval of the use of oral anticoagulant Xarelto (rivaroxaban) to reduce the risk...

A clinical trial found that Xa inhibitor edoxaban met the primary efficacy endpoint of non-inferiority compared to warfarin for the prevention of stroke or systemic embolic events (SEE) in...

acc pharmaceuticals renal denervation heart valve repair antiplatelet therapy

Clinical trials for a promising new class of cholesterol-lowering medications, a long-awaited repair of the Medicare formula for paying physicians, the Affordable Care Act, new technology and the...

CSL Behring announced that Kcentra (Prothrombin Complex Concentrate [Human]) has received U.S. Food and Drug Administration (FDA) approval for an expanded indication — urgent reversal of acquired...

clinical trial study antiplatelet thomas jefferson cath function monitors

Thomas Jefferson University researchers discovered that the formation of blood clots follows a different molecular route in African Americans versus European Americans, providing a new...

Combining genetic data with clinical information to determine the initial dosage of the blood thinner warfarin, used to prevent blood clots in the circulatory system, was no more effective in...